Journal
MOLECULAR CANCER
Volume 19, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12943-020-01258-7
Keywords
STAT3; Cancer; Immunosuppression; Immunotherapy; Immune checkpoint blockade; CAR-T
Categories
Funding
- Ministry of Science and Technology of China [2018ZX09201018-005]
- National Natural Science Foundation of China [81970561, 81502631, 81570527, 91540113]
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC18049]
- National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University [Z20191005, Z20201003]
Ask authors/readers for more resources
As a point of convergence for numerous oncogenic signaling pathways, signal transducer and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune response. STAT3 is broadly hyperactivated both in cancer and non-cancerous cells within the tumor ecosystem and plays important roles in inhibiting the expression of crucial immune activation regulators and promoting the production of immunosuppressive factors. Therefore, targeting the STAT3 signaling pathway has emerged as a promising therapeutic strategy for numerous cancers. In this review, we outline the importance of STAT3 signaling pathway in tumorigenesis and its immune regulation, and highlight the current status for the development of STAT3-targeting therapeutic approaches. We also summarize and discuss recent advances in STAT3-based combination immunotherapy in detail. These endeavors provide new insights into the translational application of STAT3 in cancer and may contribute to the promotion of more effective treatments toward malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available